Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 vs gefitinib in EGFR-mutated advanced NSCLC (China, Phase III)
CTR20160045Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2016; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20160045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160045.